Browse the evidence

Weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle interventions produces clinically significant weight loss (mean -14.9%) in adults with obesity, outperforming daily liraglutide (3.0 mg) in magnitude and duration of effect.

If you have obesity, weekly semaglutide injections (2.4 mg) combined with diet and exercise can help you lose nearly 15% of your body weight. This is significantly more effective than daily liraglutide. Start with a low dose to minimize nausea, and stick with it, as the benefits persist longer than other treatments.

Tirzepatide 15 mg administered once weekly for 72 weeks is the most cost-efficient intervention for achieving high-magnitude weight loss targets (15% and 20%) in adults with obesity, yielding a cost per kilogram of weight loss of £89.24.

For adults with obesity seeking significant weight loss, the 15mg weekly dose of tirzepatide, combined with diet and exercise, offers the best value for achieving major weight reduction goals (15-20%) over 72 weeks, despite higher initial drug costs, due to superior efficacy and potential long-term healthcare savings.

Tirzepatide 10 mg is the most cost-efficient dose for achieving moderate weight loss targets (10% and 15%) and provides competitive outcomes for BMI improvement compared to 5mg and 15mg doses.

For patients targeting moderate weight loss (10-15%), the 10mg weekly dose of tirzepatide offers a strong balance of efficacy and cost-efficiency, often outperforming lower doses and competing well with higher doses for BMI improvements.

GLP-1 receptor agonists (GLP1-RA), particularly long-acting formulations, provide superior glycaemic control, weight loss, and cardiovascular risk reduction compared to short-acting GLP1-RA, and are recommended for chronic weight management and MACE reduction.

Long-acting GLP-1 receptor agonists (like semaglutide or liraglutide) are highly effective for T2DM and weight loss. They offer better glycaemic control and fewer hypoglycemic episodes than short-acting versions. If you dislike injections, oral semaglutide is an effective alternative.

Composite meals with high fiber, low total fat, and minimal processing elicit significantly lower postprandial metabolic stress (GlucoTRIG index) compared to meals high in fat and refined foods, despite similar caloric content.

To minimize metabolic stress after a meal, prioritize high-fiber, low-fat whole foods (like beans, vegetables, and fruits) over processed foods high in fat, even if the high-fat meal has fewer carbohydrates. A meal with 58% carbohydrates but high fiber and low fat (like the study's Meal 3) was metabolically healthier than meals with lower carbohydrates but higher fat content.

Newer anti-obesity medications (GLP-1 and GLP-1/GIP agonists like semaglutide and tirzepatide) produce significantly greater weight loss (15-22.5%) compared to lifestyle modifications alone, which typically yield modest and unsustainable results.

Newer GLP-1 and GLP-1/GIP medications (like semaglutide and tirzepatide) are significantly more effective for weight loss (15-22.5%) than lifestyle changes alone. However, access is difficult due to insurance coverage, supply shortages, and cost. These medications should be viewed as a tool to help manage obesity as a chronic disease, but they still require lifestyle support and are not a 'magic pill' without side effects or administrative burdens.

GLP-1 receptor agonists (semaglutide and tirzepatide) are effective treatments for weight regain after bariatric surgery, producing clinically significant weight loss without severe adverse events.

If you regain weight after sleeve gastrectomy, GLP-1 medications like semaglutide or tirzepatide are effective and safe options to help you lose it back, avoiding the need for high-risk revisional surgery.

Tirzepatide (15 mg once weekly) combined with lifestyle counseling produces a mean weight loss of 20.9% over 72 weeks in patients with obesity or overweight.

If you are prescribed Tirzepatide (Zepbound), expect to take a 15 mg injection once weekly. This works best when combined with a 500 kcal daily caloric deficit, physical activity, and lifestyle counseling. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Semaglutide (2.4 mg once weekly) produces a mean weight loss of 14.9% over 68 weeks in patients with obesity without diabetes.

If you are prescribed Semaglutide (Wegovy), expect to take a 2.4 mg injection once weekly. This can lead to a 14.9% reduction in body weight over 68 weeks. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Liraglutide (3 mg once daily) produces a mean weight loss of 8% over 56 weeks in patients without diabetes.

If you are prescribed Liraglutide (Saxenda), expect to take a 3 mg injection once daily. This can lead to an 8% reduction in body weight over 56 weeks. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Subcutaneous semaglutide (up to 1.0 mg once-weekly) produces significantly greater reductions in BMI and waist circumference compared to liraglutide (up to 3.0 mg once-daily) in obese patients with type 2 diabetes over a 12-month period, while both agents significantly lower HbA1c.

For obese patients with type 2 diabetes, switching from or choosing semaglutide over liraglutide is likely to result in greater weight loss and waist circumference reduction. While both drugs effectively lower blood sugar, semaglutide offers superior body composition benefits. Patients should be aware that gastrointestinal side effects are common, especially with semaglutide, but these often subside as the dose is titrated up.

Obesity pharmacotherapy (GLP-1/GIP agonists) reduces body weight with minimal loss of lean mass and improves cardiovascular outcomes, potentially mitigating the adverse effects of intermittent fasting.

If you are considering obesity pharmacotherapy (like GLP-1 agonists), know that it can lead to significant weight loss (up to 21% in some trials) with minimal loss of muscle mass, which is a key advantage over intermittent fasting. It also reduces cardiovascular risk. However, long-term safety is still being studied, and combining it with lifestyle changes (diet and exercise) is recommended for the best outcomes.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) achieve weight loss magnitudes (15-20%) comparable to bariatric surgery, significantly outperforming older pharmacotherapies and single-agonist GLP-1s.

If you have obesity, newer dual-agonist medications (like tirzepatide) are currently the most effective non-surgical treatment available, offering weight loss results similar to bariatric surgery. They work by targeting multiple hormonal pathways to reduce appetite and improve metabolism. Consult a doctor to see if you qualify based on your BMI and comorbidities.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, produces significant, dose-dependent reductions in body weight, BMI, and metabolic markers in obese adults with or without type 2 diabetes.

Retatrutide is a weekly injection that significantly reduces body weight (average ~14%) and improves metabolic health in obese adults, including those with type 2 diabetes. It works by targeting three hormone receptors (GLP-1, GIP, glucagon) to reduce appetite and improve insulin sensitivity. Higher doses (8-12 mg) generally produce greater weight loss. Common side effects include nausea and vomiting, which are often manageable. It is a prescription medication requiring medical supervision.

In real-world clinical practice, tirzepatide produces significantly greater weight loss and higher rates of achieving 5%, 10%, and 15% weight reduction thresholds compared to semaglutide in adults with overweight or obesity.

If you are choosing between semaglutide and tirzepatide for weight loss, real-world data suggests tirzepatide is likely to produce roughly double the weight loss at one year compared to semaglutide. You are also significantly more likely to hit major weight loss milestones (5%, 10%, 15%) with tirzepatide. However, this comes with the caveat that these specific findings are based on formulations labeled for Type 2 Diabetes, and insurance coverage may be more difficult to obtain for tirzepatide than semaglutide.

Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, produces significant, dose-dependent weight loss in adults with obesity or overweight (≥1 comorbidity) over 13 weeks, with the 15 mg dose achieving a mean 14.7% reduction.

Take VK2735 once weekly as prescribed. Start with the lowest dose (2.5 mg) and follow the titration schedule to minimize side effects. Combine with a 500 kcal daily caloric deficit and 150 minutes of exercise per week for best results. Expect significant weight loss (up to 14.7% at 15 mg) within 13 weeks, with side effects like nausea typically subsiding after the titration phase.

Newer obesity management medications (OMMs), specifically semaglutide (2.4 mg) and tirzepatide (10-15 mg), demonstrate high efficacy comparable to metabolic bariatric surgery (MBS) in the short term (26-52 weeks), with tirzepatide achieving >15% TBWL.

For those seeking non-surgical weight loss, newer medications like semaglutide (2.4 mg) and tirzepatide (10-15 mg) are the most effective options available, with tirzepatide showing short-term weight loss (15.2%) comparable to surgical procedures. These require weekly administration and are generally more effective than older medications like orlistat. They are best used in conjunction with lifestyle interventions.

Tirzepatide demonstrates greater comparative weight loss and metabolic benefits than semaglutide in real-world observational studies, particularly in patients without pre-existing diabetes.

If you are using Semaglutide and not achieving your weight loss goals, switching to Tirzepatide may result in greater weight loss and better metabolic outcomes, especially if you do not have Type 2 Diabetes. Real-world data suggests Tirzepatide is more potent than Semaglutide in routine practice.

GLP-1/GIP co-agonists (e.g., tirzepatide) induce greater weight loss and have a more favorable gastrointestinal tolerability profile compared to GLP-1 monotherapy (e.g., semaglutide or liraglutide).

If you are considering GLP-1 therapy for obesity, discuss the potential benefits of dual agonists like tirzepatide with your provider. They may offer greater weight loss and potentially fewer gastrointestinal side effects compared to GLP-1 monotherapy, although individual responses vary.

Semaglutide 2.4 mg/week induces significant weight loss in patients with severe obesity, including those with a history of bariatric surgery, achieving outcomes comparable to or exceeding those of non-surgical patients.

If you have severe obesity, even if you have had weight loss surgery before, a weekly injection of 2.4 mg semaglutide can still help you lose weight. It is not a wasted effort due to your surgical history.

Long-term use of GLP-1 receptor agonists (semaglutide 2.4mg or tirzepatide 15mg) produces significant weight loss (4-21%) and improved cardiometabolic markers, but discontinuation leads to rapid weight regain and increased cardiac risk.

GLP-1 agonists like Wegovy and Mounjaro are highly effective for significant weight loss (up to 20%) when taken long-term. However, they are not a 'cure'; stopping the medication typically results in weight regain and increased heart disease risk. If you use these, view them as a long-term tool alongside lifestyle changes, not a quick fix.

Semaglutide (GLP-1 receptor agonist) produces significant weight loss (15.5% in adolescents, 12.5% in adults) and cardiovascular benefits, making it a prioritized treatment for those with metabolic risk factors.

Semaglutide is a highly effective weekly injection that can lead to significant weight loss (12-15%) and cardiovascular benefits. It is particularly recommended for those with metabolic risks or low satiety.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces body weight (exceeding 20% in some contexts) and improves glycemic control (HbA1c) in patients with Type 2 Diabetes and Obesity when administered via subcutaneous injection once weekly.

Tirzepatide is a once-weekly subcutaneous injection approved for Type 2 Diabetes and Obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to improve insulin sensitivity and reduce appetite. Clinical trials show it leads to significant weight loss (often >20%) and better blood sugar control than some existing drugs like semaglutide. Common side effects like nausea are usually temporary and managed by starting with a low dose and increasing slowly. It is not a standalone cure but works best with lifestyle changes.

Semaglutide 2.4 mg is a cost-effective treatment for obesity and overweight in the US, providing greater weight loss and QALYs than diet/exercise, no treatment, or other anti-obesity medications, provided the willingness-to-pay threshold is $150,000 per QALY.

For patients with obesity or overweight plus comorbidities, semaglutide 2.4 mg combined with diet and exercise is a cost-effective medical option in the US, offering significant weight loss and quality-adjusted life years compared to lifestyle changes alone or other medications, assuming a willingness-to-pay threshold of $150,000 per QALY.